Clinical Trial Update: Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating an extended-release formulation of sodium oxybate (Lumryz) for spasmodic dysphonia, laryngeal dystonia, and voice tremor; recruitment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Laryngeal Dystonia
• Spasmodic Dysphonia
• Voice Tremor

Drugs mentioned

• LUMRYZ (Sodium oxybate)

Snippet

Sponsor: Kristina Simonyan | Conditions: Spasmodic Dysphonia, Laryngeal Dystonia | Phase 1 | Status: NOT_YET_RECRUITING